NASDAQ:BCRX
BioCryst Pharmaceuticals Stock News
$4.50
-0.0800 (-1.75%)
At Close: Apr 18, 2024
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Monday, 25'th Mar 2024
RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmu
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
08:29am, Friday, 01'st Mar 2024
Each of these hidden penny stock gems have the potential to provide triple digit growth to investors. Investors are forever on the lookout for Investments that can turn $1 into $2 or more.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Monday, 26'th Feb 2024
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.38 per share a year ago.
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Wednesday, 21'st Feb 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the TD Cowen 44th Annual Health Care Con
RESEARCH TRIANGLE PARK, N.C. , Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new analyses of r
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
10:31am, Tuesday, 09'th Jan 2024
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
06:34pm, Thursday, 14'th Dec 2023
BioCryst Pharmaceuticals, Inc. proof-of-concept data from a phase 1 study, using BCX10013 for the treatment of patients with complement-mediated disorders, is expected in 2024. Oral C2, C5, and Bifunc
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Tuesday, 21'st Nov 2023
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 6th Annual Evercore ISI HealthCONx C
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO�
BioCryst to Report Third Quarter 2023 Financial Results on November 2
07:00am, Thursday, 19'th Oct 2023
RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
11:18am, Tuesday, 19'th Sep 2023
BioCryst (BCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
10:53am, Monday, 18'th Sep 2023
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé et services sociaux (INESSS) has issued a positiv
BioCryst to Present at Upcoming Investor Conferences
04:01pm, Wednesday, 23'rd Aug 2023
RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare Conferen
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
12:55pm, Thursday, 03'rd Aug 2023
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer A
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
09:48am, Thursday, 03'rd Aug 2023
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.32 per share a year ago.